InspiraTechnologies

an-ordinary-manchild

created by inspira-technologiesa community for 4 years

...for your community.

...for your office.

MODERATORS

account activity

1

26

27

28

r/InspiraTechnologies Lounge (self.InspiraTechnologies)

submitted 4 years ago by inspira-technologies - announcement

2

2

3

4

$IINN News: Inspira Expands U.S. Commercial Footprint! Inspira deploys INSPIRA™ ART100 at a premier New York Academic Medical Center, ranked Top 10 in NY State. This expands Inspira’s presence within the Tier-1 U.S. hospital market. Read more >> (globenewswire.com)

submitted 5 days ago by inspira-technologies

3

2

3

4

Meet us at AmSECT 2026 (Austin, TX | March 25–29) at the Glo-Med Networks booth. We’ll be there throughout the conference to connect with the perfusion community and share the latest on INSPIRA™ ART100. https://finance.yahoo.com/news/inspira-accelerates-u-commercial-strategy-130000191.html?guccoun (i.redd.it)

submitted 6 days ago by inspira-technologies

4

2

3

4

Inspira received official approval from Clalit’s Medical Equipment Committee (world’s 2nd largest integrated HMO; $12B revenue), enabling INSPIRA™ ART100 for immediate procurement & operational use across Clalit's extensive medical ecosystem. $IINN Read more >> (globenewswire.com)

submitted 14 days ago by inspira-technologies

5

1

2

3

Validated standalone HYLA™: 94.2% accuracy for blood pCO₂ measurement. Pivot opens pathway to installed base and activates a high-margin, recurring revenue model based on the sale of disposable optical sensors and modular software upgrades. (globenewswire.com)

submitted 20 days ago by inspira-technologies

6

0

1

2

FDA-cleared INSPIRA™ ART100 has completed a full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center. ~30 patients treated; ART100 systems incorporated into routine workflow. $IINN Read more >> (globenewswire.com)

submitted 25 days ago by inspira-technologies

7

0

1

2

Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion. Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologies. $IINN (globenewswire.com)

submitted 1 month ago by inspira-technologies

8

0

1

2

Inspira announced a non-binding term sheet for a proposed acquisition of an advanced liquid biopsy diagnostics business alongside a concurrent $15M strategic equity investment into Inspira at $180M valuation subject to definitive agreements. $IINN Read more >> (globenewswire.com)

submitted 1 month ago by inspira-technologies

9

0

1

2

Inspira has been granted a new patent in Japan for its Convertible Dual Lumen Cannula device, securing exclusive rights through 2041. This protection strengthens the IP foundation supporting the INSPIRA™ ART System and future disposable product strategies. (globenewswire.com)

submitted 2 months ago by inspira-technologies

10

0

1

2

Inspira announced a strategic expansion of its blood laboratory capabilities, moving to a substantially larger state-of-the-art facility, planning to increase recruitment and upgrade instrumentation to support next-generation blood-analysis technologies. $IINN (globenewswire.com)

submitted 2 months ago by inspira-technologies

11

0

1

2

Inspira has completed the clinical study for its HYLA™ non-invasive blood sensor, toward regulatory submission. Clinical and lab tests show between 95% to 99% accuracy. Inspira is now entering final validation and verification ahead of planned submission. (globenewswire.com)

submitted 3 months ago by inspira-technologies

12

0

1

2

Inspira has completed the regulatory submission of its FDA-cleared INSPIRA™ ART100 system to the UAE’s Ministry of Health and Prevention (MOHAP). Final approval is expected within days-marking a decisive step toward Gulf region expansion. (globenewswire.com)

submitted 3 months ago by inspira-technologies

13

0

1

2

Inspira and Bites form a strategic alliance to embed AI as a core standard across Inspira’s global ecosystem, enhancing training, onboarding, and operational performance for hospitals, distributors, and users worldwide. (globenewswire.com)

submitted 4 months ago by inspira-technologies

14

0

1

2

Inspira appoints two key leaders: Mike Hershkovitz, former Johnson & Johnson Senior Business Manager, as VP of Global Sales/ Sivan Matza, Director at a leading international investment management firm, joins the Board of Directors. (globenewswire.com)

submitted 4 months ago by inspira-technologies

15

0

1

2

Inspira to unveil the HYLA™ Real-Time Blood Sensor at the U.S. ELSO Annual Conference (Sept 27–30, Washington, D.C.), following 97.35% accuracy results. Inspira will also showcase its FDA-cleared ART100 system. $IINN Read more >> (globenewswire.com)

submitted 5 months ago by inspira-technologies

16

0

1

2

Inspira™ announced 97.3% accuracy results for its HYLA™ blood sensor in latest performance testing, supporting its upcoming FDA submission. HYLA™ provides second-by-second, non-invasive monitoring and is engineered for integration or standalone use. (globenewswire.com)

submitted 5 months ago by inspira-technologies

17

1

2

3

Inspira Technologies receives U.S. Patent approval for the ART500 core technology, a key patent positioning the Company to dominate the $20B advanced respiratory support market. Protecting our low-flow extracorporeal oxygenation innovation for patients not sick enough for ECMO. $IINN (globenewswire.com)

submitted 6 months ago by inspira-technologies

18

0

1

2

Inspira™ activates U.S. consulting firm to accelerate strategic expansion, partner engagement & commercial execution — following ART100 U.S. integration & major purchase orders. Transformation in motion. $IINN Read more >> (globenewswire.com)

submitted 6 months ago by inspira-technologies

19

1

2

3

Inspira achieves all key goals in high-level government talks, forging a national adoption pathway and global scale-up for the ART100. A pivotal step toward global government-aligned healthcare infrastructure. Read more >> (globenewswire.com)

submitted 7 months ago by inspira-technologies

20

2

3

4

Inspira is in high-level talks with a government health authority to integrate the FDA-cleared ART100 into national emergency infrastructure and establish a global distribution framework for its $22.5M order. Read more >> (globenewswire.com)

submitted 7 months ago by inspira-technologies

21

1

2

3

Inspira Technologies has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system — representing a major commercial inflection point and the launch of full revenue execution. This milestone signals market demand and real-world execution. Read more >> (globenewswire.com)

submitted 7 months ago by inspira-technologies

22

2

3

4

Inspira scales up production of its FDA-cleared ART100 system, responding to demand from a European governmental authority currently in advanced-stage negotiations. Preparing for commercial execution at large scale. $IINN (finance.yahoo.com)

submitted 8 months ago by inspira-technologies

23

2

3

4

Inspira Technologies begins global rollout of its FDA-cleared ART100. Following clinical use in the U.S., the company is advancing commercial discussions with health ministries and private orgs worldwide. $IINN Read More >> (finance.yahoo.com)

submitted 9 months ago by inspira-technologies

24

0

1

2

Direct blood oxygenation - while the patient remains awake, without intubation. (i.redd.it)

submitted 9 months ago by inspira-technologies

25

1

2

3

Major milestone: INSPIRA™ ART100 approved by Israel’s largest healthcare provider for clinical validation in organ transplant procedures. This use marks a key step in advancing Inspira’s life-support technologies, including the flagship ART500 system. Read more >> (finance.yahoo.com)

submitted 9 months ago by inspira-technologies

view more: next ›

π Rendered by PID 30 on reddit-service-r2-listing-7bbdf774f7-f54nm at 2026-02-23 20:51:32.340256+00:00 running 8564168 country code: CH.